Treatment of Mucosa Associated Lymphoid Tissue Lymphoma with a Long-Term Once-Weekly Regimen of Oral Azithromycin: Results from the Phase II MALT-A Trial
This phase II trial evaluated the efficacy and tolerability of long-term once-weekly oral azithromycin (1500 mg) in 16 patients with histologically confirmed MALT lymphoma. Patients received the regimen for up to 6 months, with restaging at 3 and 6 months. The treatment was well tolerated, with mild nausea and diarrhea
June 26, 2025
No Comments